Reportlinker Adds Pharmaceutical Key Trends 2011 - Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits
NEW YORK, April 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Pharma companies face a number of resistors to profit growth including the looming patent cliff causing a significant slowing in branded sales, coupled with ongoing R&D challenges. Pharma companies are therefore taking by boosting performance through enhancing operating profit through a combination of operating margin and sales growth.Examines the drivers and resistors facing branded pharmaceutical companiesAnalyzes M&A deals by the leading pharmaceutical companies between 2008 and 2010Examines the ongoing challenges in R&D and different strategies to overcome these hurdlesProvides an overview of various cost cutting strategies and how these are being implemented by Big PharmaWith the era of the traditional blockbuster growth model coming to an end, pharma companies are moving towards innovative, often biologic therapies for niche indications with a high unmet need, in order to gain market superiority and drive future sales growth. However, such strategies are often long-term and carry significant risk.Pharma companies are increasingly looking to expand beyond branded pharmaceuticals in the developed markets, towards generics and biosimilars, entry into the emerging markets, as well as looking outside pharmaceuticals altogether. While this can mitigate a company's risk, margins can be diluted.M&A offer the opportunity to grow scale and cut costs through elimination of duplicate operations, while externalization of R&D enables low-risk access to innovative pipeline products. Ultimately, such strategies can be used to increase profitability, although M&A at least in the long term is not a sustainable strategy.Assess the evolving R&D sector and how this is being impacted by on-going cost cutting strategies.Case study analysis of various restructuring and cost saving measures.Evaluate how M&A deals are being utilized to cut costs, drive innovation and diversify.
Executive Summary
Introduction
Strategic scoping and focus
Key findings
Key growth drivers and resistors facing healthcare payers and pharma
Pharma's strategic responses to drive sales and profitability
Cost-cutting strategies
M&A utilized to cut costs, drive innovation, and diversification
Pharma continues to battle with R&D issues
Related reports
Upcoming related reports
COST CUTTING
Pharma cuts costs to improve profitability
Cost-cutting has ultimately led to site closures and job cuts
Restructuring and greater externalization continues to impact employment levels in pharma
Pharma continues to cut R&D and manufacturing sites
Mega-M&A used to grow scale and cut costs
CMOs and CROs set to capitalize on the growing need to reduce in-house R&D and manufacturing
CMO market set to boom but inspections must increase
Fragmented CRO market set to become more competitive
Restructuring as part of a shift in R&D focus led to site closures
Bristol-Myers Squibb is divesting its ex-pharma units to increase operating margins and generate cash for a small acquisition
Pharma cuts promotional budgets for expiring blockbusters
Reducing bonuses is an alternative option to cost cutting
MERGERS AND ACQUISITIONS
M&A activity has bounced back
M&A utilized to cut costs, drive innovation, and diversification
Big Pharma M&A to enhance focus on specialty pharmaceuticals
M&A driven by diversification/specialization
Mega-M&A deals to cut costs and increase scale
RESEARCH AND DEVELOPMENT
Pharma continues to battle with R&D issues
Falling productivity and growing costs hamper pharma's R&D
The Obama administration aims to accelerate early-stage research
R&D spend continues to grow in a desperate effort to replenish pipelines
Pharma is increasingly externalizing R&D to cut costs and mitigate risks
Pharma's level of early-stage R&D collaboration intensifies
R&D outsourcing and offshoring to grow further as pharma's focus on cost-containment heightens
Pharma sharpens its focus on secondary care indications through high value biologic therapies
Restructuring driven by thinning pipelines
Drug approvals dipped in 2010
Orphan drug designations reached a record high in 2010
Key Big Pharma players targeting niche pharma markets
Key technologies utilized by pharma when targeting rare diseases
Development of RNAi therapies among major industry players has stalled
Companion diagnostics can optimize the commercial potential of novel drugs
2010 marked the beginning of a new era for stem cell research, with 2011 looking to be even more promising
Biotech show signs of recovery
Biotech financing shows steady growth driven by greater levels of debt financing
Biotech IPOs point to a gradual recovery in investor confidence
However, IPOs were less lucrative than anticipated
Fewer bankruptcies in 2010 reflect an improving funding environment for biotechs
BIBLIOGRAPHY
Publications and online articles
Datamonitor reports and products
APPENDIX
Exchange rates used in this report
To order this report:
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article